Fused hexacyclic imidazole derivatives as modulators of TNF activity

A compound of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof:

• wherein
• A represents C—R6;
• B represents C—R7;
• D represents C—R8;
• —(X-M-Q)- represents an optionally substituted five-membered heteroaromatic ring selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl and tetrazolyl optionally substituted by one, two or three substituents selected from C1-6 alkyl, trifluoromethyl, hydroxy and oxo;
• Z represents methylene;
• E represents a fused heteroaromatic ring system of formula (Ea)
• wherein the asterisks (*) represent the site of attachment of E to the remainder of the molecule;
• R1 represents chloro;
• or R1 represents pyrimidinyl, cyclobutylpyridinyl, cyclopentylpyridinyl, cyclobutylpyrimidinyl, azetidinylpyrimidinyl or piperazinyl-pyrimidinyl, any of which groups may be optionally substituted by one two or three substituents independently selected from halogen, trifluoromethyl, hydroxy, hydroxy(C1-6)alkyl, oxo, amino and amino(C1-6)alkyl;
• R2 represents hydrogen or halogen;
• R3 and R4 independently represent hydrogen, halogen or or C1-6 alkyl;
• R5 represents difluoro-methoxy or methoxy;
• R6 represents hydrogen, halogen or trifluoromethyl;
• R7 represents hydrogen or trifluoromethyl;
• R8 represents hydrogen or trifluoromethyl;
• and
• R12 represents hydrogen or C1-6 alkyl.